These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31266370)

  • 1. Abrupt Increase in Reporting of Neoplasms Associated with Valsartan After Medication Recall.
    Al-Kindi SG; Oliveira GH
    Circ Cardiovasc Qual Outcomes; 2019 Jul; 12(7):e005536. PubMed ID: 31266370
    [No Abstract]   [Full Text] [Related]  

  • 2. Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.
    Gillette M; Taylor A; Butulija D; Kadiyala H; Jneid H
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):579-584. PubMed ID: 32318933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
    Charoo NA; Ali AA; Buha SK; Rahman Z
    AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.
    Pottegård A; Kristensen KB; Ernst MT; Johansen NB; Quartarolo P; Hallas J
    BMJ; 2018 Sep; 362():k3851. PubMed ID: 30209057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
    Cohen Sedgh R; Moon J; Jackevicius CA
    Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recall of N-Nitrosodimethylamine-Contaminated Pseudogeneric Valsartan: Best Generics Finally No Better Than Others?
    Leclerc J
    Can J Cardiol; 2018 Oct; 34(10):1370.e13. PubMed ID: 30269837
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.
    Salim H; Jones AM
    Br J Clin Pharmacol; 2022 Nov; 88(11):4812-4827. PubMed ID: 35585835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
    Byrd JB; Chertow GM; Bhalla V
    N Engl J Med; 2019 Apr; 380(17):1589-1591. PubMed ID: 30865819
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database
.
    Fujimoto M; Kanou M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2017 Apr; 55(4):295-303. PubMed ID: 28079518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointerestinal: Valsartan induced sprue-like enteropathy.
    Soldera J; Salgado K
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1262. PubMed ID: 31916293
    [No Abstract]   [Full Text] [Related]  

  • 12. [Valsartan contamination].
    Jilesen DPMW; Kramers C; Kerkvliet CTM; Bosch FH
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.
    McAdams MA; Governale LA; Swartz L; Hammad TA; Dal Pan GJ
    Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):882-9. PubMed ID: 18636418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.
    Lou-Meda R; Stiller B; Antonio ZL; Zielinska E; Yap HK; Kang HG; Tan M; Glazer RD; Valentin MA; Wang L
    Pediatr Nephrol; 2019 Mar; 34(3):495-506. PubMed ID: 30397789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Drug-Induced Photosensitivity Using the Japanese Adverse Drug Event Report (JADER) Database.
    Nakao S; Hatahira H; Sasaoka S; Hasegawa S; Motooka Y; Ueda N; Abe J; Fukuda A; Naganuma M; Kanoh H; Seishima M; Ishiguro M; Kinosada Y; Nakamura M
    Biol Pharm Bull; 2017; 40(12):2158-2165. PubMed ID: 29199239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.
    Paton DM
    Drugs Today (Barc); 2017 Jan; 53(1):19-26. PubMed ID: 28387384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Qi WW; Liu T; Xu G; Li LF; Liang YZ; Ye L; Li GP
    Trials; 2015 Aug; 16():336. PubMed ID: 26248619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG; Rector TS; Anand IS; Cohn JN
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
    Jo YI; Na HY; Moon JY; Han SW; Yang DH; Lee SH; Park HC; Choi HY; Lim SD; Kie JH; Lee YK; Shin SK
    Korean J Intern Med; 2016 Mar; 31(2):335-43. PubMed ID: 26874511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.